10-QPeriod: Q2 FY2006

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2006

Filed August 10, 2006For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed its 10-Q for the period ending June 30, 2006, on August 10, 2006. The filing provides an unaudited look at the company's financial performance for the second quarter and first half of the fiscal year, along with management's discussion and analysis. Investors should pay close attention to the "Management's Discussion and Analysis of Financial Condition and Results of Operations" for insights into the drivers of financial performance, including revenue trends, cost management, and any significant operational developments. The report also details the company's financial position on the balance sheet and cash flow generation during the period. Key areas of interest for investors include the company's product sales performance, particularly for its key drugs, any updates on research and development pipelines, and an assessment of the company's liquidity and capital resources. The "Legal Proceedings" and "Risk Factors" sections in Part II are crucial for understanding potential challenges and uncertainties that could impact future results. Investors seeking a comprehensive understanding should review all sections, but focus on the financial statements, MD&A, and risk-related disclosures.

Key Highlights

  • 1The filing contains unaudited condensed consolidated financial statements for the three and six months ended June 30, 2006, compared to the same periods in 2005.
  • 2Management's Discussion and Analysis (MD&A) provides insights into the company's financial condition, results of operations, and liquidity.
  • 3Key financial statements include Statements of Operations, Balance Sheets, and Statements of Cash Flows.
  • 4The report includes disclosures on market risk, controls and procedures, and legal proceedings.
  • 5Risk factors that could affect the company's future performance are detailed in Part II, Item 1A.

Frequently Asked Questions

This 10-Q filing provides investors with an unaudited update on Biogen Inc.'s financial performance and condition for the second quarter and first half of the fiscal year ending June 30, 2006. It includes financial statements, management's analysis of results, and other relevant business information.

The "Management's Discussion and Analysis of Financial Condition and Results of Operations" (Item 2) is the primary section for understanding the factors that influenced the company's financial results, including revenue, expenses, and significant business developments.

Investors should examine the Condensed Consolidated Statements of Operations for revenue and profitability trends, the Condensed Consolidated Balance Sheets for the company's asset and liability position, and the Condensed Consolidated Statements of Cash Flows for its cash generation and usage during the period.

The "Risk Factors" section (Part II, Item 1A) outlines potential challenges and uncertainties that could materially affect Biogen's business, financial condition, or results of operations. This could include factors related to product development, competition, regulatory approvals, and market dynamics.